|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Computed tomography-guided percutaneous core needle biopsy in pancreatic tumor diagnosis显示文摘AIM: To evaluate the techniques, results, and complications related to computed tomography(CT)-guided percutaneous core needle biopsies of solid pancreatic lesions.METHODS: CT-guided percutaneous biopsies of solid pancreatic lesions performed at a cancer reference center between January 2012 and September 2013 were retrospectively analyzed. Biopsy material was collected with a 16-20 G Tru-Core needle(10-15 cm; Angiotech, Vancouver, CA) using a coaxial system and automatic biopsy gun. When direct access to the lesion was not possible, indirect(transgastric or transhepatic) access or hydrodissection and/or pneumodissection maneuvers were used. Characteristics of the patients, lesions, procedures, and histologic results were recorded using a standardized form. RESULTS: A total of 103 procedures included in the study were performed on patients with a mean age of 64.8 year(range: 39-94 year). The mean size of the pancreatic lesions was 45.5 mm(range: 15-195 mm). Most(75/103, 72.8%) procedures were performed via direct access, though hydrodissection and/or pneumodissection were used in 22.2%(23/103) of cases and indirect transhepatic or transgastric access was used in 4.8%(5/103) of cases. Histologic analysis was performed on all biopsies, and diagnoses were conclusive in 98.1%(101/103) of cases, confirming3.9%(4/103) of tumors were benign and 94.2%(97/103) were malignant; results were atypical in 1.9%(2/103) of cases, requiring a repeat biopsy to diagnose a neuroendocrine tumor, and surgical resection to confirm a primary adenocarcinoma. Only mild/moderate complications were observed in 9/103 patients(8.7%),and they were more commonly associated with biopsies of lesions located in the head/uncinate process(n =8), than of those located in the body/tail(n = 1) of the pancreas, but this difference was not significant.CONCLUSION: CT-guided biopsy of a pancreatic lesion is a safe procedure with a high success rate, and is an excellent option for minimally invasive diagnosis. | Chiang J Tyng Maria Fernanda A Almeida Paula NV Barbosa Almir GV Bitencourt José Augusto AG Berg Macello S Maciel Felipe JF Coimbra Luiz Henrique O Schiavon Maria Dirlei Begnami Marcos D Guimares Charles E Zurstrassen Rubens Chojniak | 2015 | World Journal of Gastroenterology2015，21，12： | 14 |
| 2 | BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer显示文摘 | Taron M Rosell R Felip E | | 0，，20： | 2 |
| 3 | The role of chemotherapy in early non-small cell lung cancer management显示文摘 | Rosell R FeliP E Maestre J | 2001 | Lung Cancer2001，34，13： | 1 |
| 4 | Oxygen sensitivity of cloned voltage-gated K + channels expressed in the pulmonary vasculature 显示文摘 | Hulme J T Coppock E A Felipe A | 1999 | Circulation Research1999，85，： | 1 |
| 5 | Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer显示文摘 | Felip E Rosell R Maestre JA | 2010 | J Clin Oncol2010，28，19： | 1 |
| 6 | Drug development to overcome resistance to EGFR inhibitors in lung and colorectal caner 显示文摘 | Dienstmann R de Dosso S Felip E | 2012 | Mol Oncol2012，6，1： | 1 |
| 7 | The developing cancer stem-cell model: clinical challenges and opportunities显示文摘 | Louis Vermeulen Felipe de Sousa e Melo Dick J Richel Jan Paul Medema | 2012 | Lancet Oncology2012，，： | 1 |
| 8 | Small-cell lung cancer:ESMO clinical recommendations for diagnosis,treatment and follow-up显示文摘 | S(o)rensen M Felip E ESMO Guidelines Working Group | 2009 | Ann Oncol2009，204，： | 1 |
| 9 | ESMO minimum clinical recommendations for diagnosis, treatment and follow- up of non - small cell lung cancer(NSCLC) 显示文摘 | Felip E Stahel RA Pavlidis N | 2005 | Ann Oncol2005，，： | 1 |
| 10 | A novel anti-apoptesis gene:Re-expression of Survivin messenger RNA as aprognosis marker in non-small-cell lung cancers显示文摘 | Monzo M Resell R Felip E | 1999 | J Clin Oncol1999，17，7： | 1 |
| 11 | Ganitumab for the treat ment of small-cell lung cancer 显示文摘 | Martinez P Sales Fidalgo PA Felip E | 2014 | Expert Opin Investig Drugs2014，23，10： | 1 |
| 12 | A novel anti-apoptosis gene: re- expression of survivin messenger RNA as a prognosis marker in non- small-cell lung cancers 显示文摘 | Monzo M Rosell R Felip E | 1999 | J Clin Oncol1999，17，7： | 1 |
| 13 | Study of the true clinical progression of autosomal dominant Alport syndrome in a European population 显示文摘 | Rosado C Bueno E Felipe C | 2015 | Kidney Blood Press Res2015，40，4： | 1 |
| 14 | A novel anti-apoptosis gene:Re-ex pression of Survivin messager RNA as a prognosis marker in non-small cell lung cancers显示文摘 | Monzo M Rosell R Felip E | 1999 | J Clin Oncol1999，17，7： | 1 |
| 15 | A novel anti-apoptosis gene:re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers显示文摘 | Monzo M Rosell R Felip E | 1999 | J Clin Oncol1999，17，7： | 1 |
| 16 | Cavitary pulmonary metastases in transitional cell carcinoma of urinary bladder 显示文摘 | Rovirosa A Salud A Felip E | 1992 | Urol Int1992，48，1： | 1 |
| 17 | BRCA1 mRNAexpression levelsasan indicator of chemoresistance in lungcancer 显示文摘 | Taron M Rosell R Felip E | 2004 | Hum Mol Genet2004，13，20： | 1 |
| 18 | ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK- rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ)显示文摘 | Mok T Spigel D Felip E | 2015 | J Clin Oncol2015，33，： | 1 |
| 19 | Gene expression as a predictive marker of outcome in stage IIB- IIIA- IIIB non - small cell lung cancer after induction gemcitabine - based chemotherapy followed by resectional surgery 显示文摘 | Rosell R Felip E Taron M | 2004 | Clin Cancer Res2004，10，： | 1 |
| 20 | Co translational,in- traribosomal cleavage of polypeptides by the foot-and mouth dis ease virus 2A peptide显示文摘 | De Felipe P Hughes L E Ryan M D | 2003 | J Biol Chem2003，278，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员